Modified-Release Oral Minoxidil for Prolonged Serum Exposure
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments for hair loss, such as topical minoxidil, often result in rapid absorption and short duration of action, leading to suboptimal therapeutic effects and potential adverse effects.
Innovation Solution
A modified release formulation of minoxidil or its pharmaceutically acceptable salt, designed for oral administration, which releases 50% to 98% of the daily dose within 12 hours, with a Tmax of 30 to 360 minutes and Cmax of 0.25 ng/ml to 20 ng/ml, providing sustained pharmacokinetic profiles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If topical minoxidil is used for hair loss treatment, then the treatment can be applied locally, but the absorption is rapid and the duration of action is short
Solution Approach 1:
The patent segments the minoxidil delivery system into multiple dosage forms (topical formulations, oral formulations, transdermal patches, microencapsulated systems) that release the active ingredient at different rates. This segmentation allows optimization of both immediate therapeutic effect and prolonged duration of action through coordinated release mechanisms.
Solution Approach 2:
The patent changes the release rate parameter of minoxidil from rapid to controlled/sustained release through various formulation strategies including use of polymers, lipids, and delivery vehicles that modulate the release kinetics. This parameter change extends the duration of action while maintaining therapeutic efficacy.
2Speed
If rapid absorption formulations are used, then the onset of action is quick, but the therapeutic effect is suboptimal and adverse effects occur
Solution Approach 1:
The patent employs periodic or pulsatile release mechanisms where minoxidil is delivered in controlled bursts or at intervals, preventing continuous high-level exposure that causes adverse effects while maintaining sufficient drug levels for therapeutic action. This includes formulations that release drug in response to specific physiological triggers.
Solution Approach 2:
The patent introduces intermediary substances such as penetration enhancers, carriers, and delivery vehicles that mediate between the rapid absorption tendency of minoxidil and the need for controlled delivery. These intermediaries modulate the release rate and reduce direct tissue exposure that causes adverse effects.
3Duration of action of moving object
If modified release formulation is used to extend duration, then therapeutic effects are prolonged, but the formulation complexity increases
Solution Approach 1:
The patent utilizes porous materials such as porous polymers, ceramics, and matrices as simple yet effective modified release systems. These materials provide controlled diffusion pathways for minoxidil release without requiring complex mechanical or chemical mechanisms, thus extending duration while minimizing formulation complexity.
Solution Approach 2:
The patent employs composite materials combining minoxidil with polymers, lipids, or other carriers that inherently provide modified release properties. These composite systems achieve prolonged duration of action through the inherent properties of the composite structure rather than complex delivery mechanisms.
Data Source
AI summary
The compositions and methods provided herein include a pharmaceutical formulation for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Also provided herein are pharmaceutical formulations for oral administration comprising a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof and one or more additional active agents. Also provided herein are methods of treating hair loss by administering to a subject in need thereof a daily dose of a modified release formulation of minoxidil or a pharmaceutically acceptable salt thereof. Further provided herein is a kit including a slow modified release vehicle comprising oral minoxidil or a pharmaceutically acceptable salt thereof.